DiscoveryProbe™ FDA-approved Drug Library: High-Content Screening and Drug Repositioning Resource

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 clinically approved small molecules, each extensively characterized for mechanism of action and regulatory status (ApexBio). The library supports high-throughput and high-content screening (HTS/HCS) for drug repositioning and novel pharmacological target identification (He et al., 2023). Compounds are provided as stable 10 mM DMSO solutions, validated for 12 months at -20°C or 24 months at -80°C. The L1021 kit has enabled the identification of pro-apoptotic agents for cancer research, including colorectal cancer, via BRET-based screening approaches. The resource is optimized for integration into automated workflows for both academic and translational research.

Biological Rationale

Drug discovery increasingly relies on repositioning clinically approved compounds to accelerate therapeutic development. FDA-approved drug libraries provide a unique opportunity to identify new uses for existing medications, leveraging established safety and pharmacokinetic profiles (He et al., 2023). The DiscoveryProbe™ FDA-approved Drug Library aggregates 2,320 bioactive molecules, including receptor agonists, antagonists, enzyme inhibitors, ion channel modulators, and signaling pathway regulators. Comprehensive coverage ensures inclusion of compounds approved by the FDA, EMA, HMA, CFDA, and PMDA, or those listed in major pharmacopeias (ApexBio product page). Representative drugs such as doxorubicin (anticancer), metformin (antidiabetic), and atorvastatin (lipid-lowering) span a broad range of clinical indications and mechanisms.

High-throughput and high-content screening approaches require compound collections with well-annotated mechanisms and clinical validation. The DiscoveryProbe™ library supports research in oncology, neurodegeneration, infectious disease, and rare disorders, facilitating target discovery and validation in diverse model systems. The resource is particularly valuable for enabling studies of cell signaling, apoptosis, and drug resistance mechanisms in disease models.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ library contains small molecules with diverse and well-documented mechanisms of action. These include:

• Receptor agonists/antagonists (e.g., beta-blockers, opioid antagonists) that modulate cellular signaling pathways.
• Enzyme inhibitors (e.g., kinase, protease, or BCL-2 inhibitors) that disrupt metabolic or apoptotic pathways.
• Ion channel modulators affecting neuronal or cardiac excitability.
• Signal pathway regulators acting on pathways such as PI3K/AKT, MAPK, and intrinsic apoptosis.

For example, compounds like venetoclax (BCL-2 inhibitor) induce apoptosis by inhibiting anti-apoptotic proteins, while metformin activates AMP-activated protein kinase (AMPK) to modulate cellular metabolism (He et al., 2023). The library's chemical diversity enables interrogation of multiple pharmacological targets, supporting both target-based and phenotypic screening strategies.

Evidence & Benchmarks

• A BRET-based high-throughput screening of an FDA-approved drug library (n=1971 compounds) identified terfenadine, penfluridol, and lomitapide as disruptors of 14-3-3:BAD interactions in colorectal cancer cells (He et al., 2023).
• The DiscoveryProbe™ library is provided as aliquoted 10 mM DMSO solutions, stable for 12 months at -20°C and 24 months at -80°C, facilitating reproducibility (ApexBio).
• Screening with the L1021 kit in NIH3T3 fibroblasts and HT-29/Caco-2 colorectal cancer lines demonstrated feasibility for pro-apoptotic agent identification (He et al., 2023).
• The library's compound set covers drugs approved by the FDA, EMA, HMA, CFDA, and PMDA, or listed in global pharmacopeias, ensuring regulatory diversity (ApexBio).
• High-throughput screening using the DiscoveryProbe™ library achieves a Z’-score of 0.52 in BRET assays, indicating robust assay performance (He et al., 2023).

This article updates DiscoveryProbe™ FDA-approved Drug Library: High-Content S... by providing new peer-reviewed evidence from BRET-based screening in cancer models and offering expanded integration guidance. For a discussion of advanced neurodegenerative disease applications, see DiscoveryProbe FDA-approved Drug Library: Enabling Next-...; this article highlights translational oncology and mechanistic screening benchmarks.

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is applied in:

• Drug repositioning screening for new indications of approved drugs (He et al., 2023).
• High-throughput and high-content screening in disease models (e.g., cancer, neurodegeneration).
• Pharmacological target identification using phenotypic or target-based assays.
• Signal pathway regulation studies for elucidating cellular mechanisms.
• Enzyme inhibitor and apoptosis modulation screening.

Its ready-to-use, stable format enables direct integration into automated screening systems. The library's compound annotation enables precise mapping of hits to biological pathways and clinical indication space.

Common Pitfalls or Misconceptions

• The library does not include investigational drugs or compounds lacking regulatory approval; only clinically approved or pharmacopeia-listed agents are present.
• Results from in vitro screening may not translate directly to in vivo efficacy due to differences in metabolism and pharmacokinetics.
• High-throughput screens require orthogonal validation to confirm specificity and mechanism of hit compounds.
• The standard format (10 mM DMSO) may not be suitable for assays sensitive to DMSO or requiring aqueous solutions without additional preparation.
• The library is not intended for direct clinical use; all compounds require proper handling and disposal in a research setting.

Workflow Integration & Parameters

The DiscoveryProbe™ library is available in 96-well microplates, deep-well plates, and 2D barcoded screw-top tubes for flexible workflow integration. Compounds are delivered as 10 mM DMSO solutions, compatible with most liquid-handling robotics. Storage at -20°C (12 months) or -80°C (24 months) preserves compound integrity. Shipping options include blue ice for evaluation samples and room temperature or blue ice upon request for larger orders.

To maximize reproducibility, thaw compounds at room temperature and minimize freeze-thaw cycles. Automated HTS/HCS platforms can accommodate the standard plate formats for rapid screening. Detailed compound annotation enables immediate downstream bioinformatics analysis. For advanced guidance on integrating mechanistic screening with translational endpoints, see Translational Powerhouse: Mechanistic Drug Discovery and ...; this article extends those concepts with detailed workflow-specific QC recommendations.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) provides a standardized, regulatory-diverse resource for high-throughput screening, drug repositioning, and pharmacological investigations. Its clinical annotation, stability, and workflow-friendly formats make it a cornerstone tool for translational research. Recent evidence from BRET-based HTS in colorectal cancer models demonstrates its capacity to uncover actionable therapeutic leads (He et al., 2023). As compound annotation and cheminformatics integration improve, the library is poised to accelerate discoveries across oncology, neurodegeneration, and beyond. For full product details and ordering information, consult the DiscoveryProbe™ FDA-approved Drug Library product page.